

PHAYM055: Pharmacology 1 (Masters Level): Pharmacology and CNS disorders

[View Online](#)

[1]

K. S. Smith and U. Rudolph, 'Anxiety and depression: Mouse genetics and pharmacological approaches to the role of GABAA receptor subtypes', *Neuropharmacology*, vol. 62, no. 1, pp. 54–62, Jan. 2012, doi: 10.1016/j.neuropharm.2011.07.026.

[2]

B. Luscher, Q. Shen, and N. Sahir, 'The GABAergic deficit hypothesis of major depressive disorder', *Molecular Psychiatry*, vol. 16, no. 4, pp. 383–406, Apr. 2011, doi: 10.1038/mp.2010.120.

[3]

R. Balon, 'Mood, anxiety, and physical illness: body and mind, or mind and body?', *Depression and Anxiety*, vol. 23, no. 6, pp. 377–387, 2006, doi: 10.1002/da.20217.

[4]

A. V. Kalueff and D. J. Nutt, 'Role of GABA in anxiety and depression', *Depression and Anxiety*, vol. 24, no. 7, pp. 495–517, 2007, doi: 10.1002/da.20262.

[5]

J. F. Cryan and K. Kaupmann, 'Don't worry "B" happy!: a role for GABAB receptors in anxiety and depression', *Trends in Pharmacological Sciences*, vol. 26, no. 1, pp. 36–43, Jan. 2005, doi: 10.1016/j.tips.2004.11.004.

[6]

A. Holmes, M. Heilig, N. M. J. Rupniak, T. Steckler, and G. Griebel, 'Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders', *Trends in Pharmacological Sciences*, vol. 24, no. 11, pp. 580–588, Nov. 2003, doi: 10.1016/j.tips.2003.09.011.

[7]

J. Levine, D. P. Cole, K. N. R. Chengappa, and S. G. M.D., 'Anxiety disorders and major depression, together or apart', *Depression and Anxiety*, vol. 14, no. 2, pp. 94–104, 2001, doi: 10.1002/da.1051.

[8]

T. F. Freund, 'Interneuron Diversity series: Rhythm and mood in perisomatic inhibition', *Trends in Neurosciences*, vol. 26, no. 9, pp. 489–495, Sep. 2003, doi: 10.1016/S0166-2236(03)00227-3.

[9]

P. G. Strange, *Brain biochemistry and brain disorders*. Oxford: Oxford University Press, 1992.

[10]

A. F. Carvalho and E. J. Van Bockstaele, 'Cannabinoid modulation of noradrenergic circuits: Implications for psychiatric disorders', *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, vol. 38, no. 1, pp. 59–67, Jul. 2012, doi: 10.1016/j.pnpbp.2012.01.008.

[11]

B. K. Atwood, A. Straiker, and K. Mackie, 'CB2: Therapeutic target-in-waiting', *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, vol. 38, no. 1, pp. 16–20, Jul. 2012, doi: 10.1016/j.pnpbp.2011.12.001.

[12]

A. J. Hill, C. M. Williams, B. J. Whalley, and G. J. Stephens, 'Phytocannabinoids as novel therapeutic agents in CNS disorders', *Pharmacology & Therapeutics*, vol. 133, no. 1, pp. 79–97, Jan. 2012, doi: 10.1016/j.pharmthera.2011.09.002.

[13]

'Sodium oxybate: a primer for pharmacists in the treatment of narcolepsy'. [Online].

Available:

https://www.researchgate.net/profile/Kimberley_Begley2/publication/265473606_Sodium_Oxybate_A_Primer_for_Pharmacists_in_the_Treatment_of_Narcolepsy/links/54dceb110cf25b09b912dd40.pdf

[14]

O. A. H. Attarian, 'Treatment of disorders of hypersomnolence', vol. 16, no. 9, pp. 302–302

[Online]. Available:

http://download.springer.com/static/pdf/61/art%253A10.1007%252Fs11940-014-0302-9.pdf?auth66=1414068132_049751e80fe3aa485ba574ca1df01580&ext=.pdf

[15]

K. J. P. N.P. Robertson, 'Narcolepsy: environment, genes and treatment', vol. 261, no. 8,

pp. 1644–1646, 2014 [Online]. Available:

<http://link.springer.com.libproxy.ucl.ac.uk/article/10.1007/s00415-014-7435-3/fulltext.html>

[16]

N. Cera, A. Tartaro, and S. L. Sensi, 'Modafinil Alters Intrinsic Functional Connectivity of the Right Posterior Insula: A Pharmacological Resting State fMRI Study', *PLoS ONE*, vol. 9, no. 9, Sep. 2014, doi: 10.1371/journal.pone.0107145.

[17]

C. B. Saper and T. E. Scammell, 'Emerging therapeutics in sleep', *Annals of Neurology*, vol. 74, no. 3, pp. 435–440, Aug. 2013, doi: 10.1002/ana.24000.

[18]

K. R. Eric J. Olson, 'Management of common sleep disorders', vol. 88, no. 4, pp. 231–238, 2013 [Online]. Available: <http://www.aafp.org/afp/2013/0815/p231.pdf>

[19]

D. Hoyer and L. H. Jacobson, 'Orexin in sleep, addiction and more: Is the perfect insomnia drug at hand?', *Neuropeptides*, vol. 47, no. 6, pp. 477–488, Dec. 2013, doi: 10.1016/j.npep.2013.10.009.

[20]

M. W. M. Carlos H. Schenck, 'Insights from studying human sleep disorders', vol. 437, no. 7063, pp. 1279–1285, 2005 [Online]. Available: <http://www.nature.com.libproxy.ucl.ac.uk/nature/journal/v437/n7063/pdf/nature04287.pdf>

[21]

G. Stores, 'Medication for sleep-wake disorders', *Archives of Disease in Childhood*, vol. 88, no. 10, pp. 899–903, Oct. 2003, doi: 10.1136/adc.88.10.899.

[22]

T. S. Kilduff and C. Peyron, 'The hypocretin/orexin ligand-receptor system: implications for sleep and sleep disorders', *Trends in Neurosciences*, vol. 23, no. 8, pp. 359–365, Aug. 2000, doi: 10.1016/S0166-2236(00)01594-0.

[23]

C. Brisbare-Roch, 'Promotion of sleep by targeting the orexin system in rats, dogs and humans', vol. 13, no. 2, pp. 150–155, 2007 [Online]. Available: <http://www.nature.com.libproxy.ucl.ac.uk/nm/journal/v13/n2/pdf/nm1544.pdf>

[24]

Mark W. Mahowald MD, 'Pathophysiologic mechanisms in REM sleep behavior disorder', *Current Neurology and Neuroscience Reports*, vol. 7, no. Issue 2, pp. 167–172, Mar. 2007, doi: 10.1007/s11910-007-0013-7. [Online]. Available: <http://link.springer.com.libproxy.ucl.ac.uk/article/10.1007/s11910-007-0013-7>

[25]

M. W. Mahowald and C. H. Schenck, 'Dissociated states of wakefulness and sleep', *Neurology*, vol. 42 Suppl. 6, pp. 44-52, 1992 [Online]. Available: <http://ovidsp.uk.ovid.com/sp-3.29.1a/ovidweb.cgi?QS2=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>